Summary
Six healthy volunteers were given probenecid 0.5, 1 and 2 g p.o. and 0.5 g i.v. The protein binding of probenecid at different concentrations in human plasma was estimated by equilibrium dialysis. The free fraction was found to increase nonlinearly with increasing total probenecid concentration, up to a maximum free fraction of 26%. The plasma concentration-time data after the oral doses were described by a one-compartment open model with first-order absorption and Michaelis-Menten elimination. The mean absorption rate constant 0.0072 min−1 was dose-independent, and the maximal rate of elimination (mean 1429 µg/min) did not differ between doses whether calculated from the total or free concentrations. The Michaelis-Menten constant decreased significantly from 67.1 to 55.5 µg/ml as the dose increased from 1 g to 2 g, while the unbound Michaelis-Menten constant remained unchanged. The elimination of probenecid after the 0.5 g dose was in the linear region of the Michaelis-Menten elimination when calculated from the total and the free concentrations. The volume of distribution increased only slightly from 9.5 to 11.4 l as the dose increased from 0.5 to 2 g, but the unbound volume of distribution decreased significantly from 164 to 99 l. Absorption was complete and was independent of the dose administered.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bachmann K, Sullivan TJ (1982) Effect of plasma protein binding on clearance of drugs metabolized by Michaelis-Menten kinetics. J Pharm Sci 71: 374–375
Chiang C-WN, Benet LZ (1981) Dose-dependent kinetics of probenecid in rhesus monkeys — intravenous bolus studies. Pharmacology 23: 326–336
Chiang C-WN, Benet LZ (1984) Dose-dependent kinetics of probenecid in rhesus monkeys — infusion studies. Pharmacology 28: 181–187
Conway WD, Melethil S (1974) Excretion of probenecid and its metabolites in bile and urine of rats. J Pharm Sci 63: 1551–1554
Cunningham RF, Israili ZH, Dayton PG (1981) Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 6: 135–151
Cunningham RF, Perel JM, Israili ZH, Dayton PG (1977) Probenecid metabolism in vitro with rat, mouse, and human liver preparations. Studies of factors affecting the site of oxidation. Drug Metab Disposit 5: 205–210
Dayton PG, Yü TF, Chen W, Berger L, West LA, Gutman AB (1963) The physiological disposition of probenecid, including renal clearance, in man, studied by an improved method for its estimation in biological material. J Pharmacol Exp Ther 140: 278–286
Dayton PG, Cucinell SA, Weiss M, Perel JM (1967) Dose-dependence of drug plasma level decline in dogs. J Pharmacol Exp Ther 158: 305–316
Dayton PG, Perel JM (1971) The metabolism of probenecid in man. Ann NY Acad Sci 179: 399–402
Dayton PG, Perel JM, Cunningham RF, Israili ZH, Weiner IM (1973) Studies of the fate of metabolites and analogs of probenecid. The significance of metabolic sites, especially lack of ring hydroxylation. Drug Metab Disposit 6: 742–751
Ehrnebo M, Agurell S, Jalling B, Boreus LO (1971) Age differences in drug binding by plasma proteins: Studies on human foetuses, neonates and adults. Eur J Clin Pharmacol 3: 189–193
Elghozi JL, Mignot E, Le Quan-Biu KH (1983) Probenecid sensitive pathway of elimination of dopamine and serotonin metabolites in CSF of the rat. J Neural Transm 57: 85–94
Emanuelsson B-M, Paalzow L (1986) Dose-dependent pharmacokinetics of probenecid in the rat. Eur J Pharmacol
Gillette JR (1971) Factors affecting drug metabolism. Ann NY Acad Sci 179: 43–66
Gibaldi M, McNamara PJ (1978) Apparent volumes of distribution and drug binding to plasma proteins and tissues. Eur J Clin Pharmacol 13: 373–378
Guentert TW (1984) Pharmacokinetics of benzodiazepines and of their metabolites. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism 8. Taylor and Francis, London Philadelphia, pp 241–386
Hartvig P, Fagerlund C, Emanuelsson B-M (1982) Extractive alkylation of probenecid in plasma and cerebrospinal fluid and determination by electron-capture gas chromatography. J Chromatogr 228: 340–345
Jusko WJ, Koup JR, Alvan G (1976) Nonlinear assessment of phenytoin bioavailability. J Pharmacokinet Biopharm 4: 327–336
Levy G (1965) Pharmacokinetics of salicylate elimination in man. J Pharm Sci 50: 959–967
Martis L, Levy RH (1973) Bioavailability calculations for drugs showing simultaneous first-order and capacity-limited elimination kinetics. J Pharmacokinet Biopharm 1: 283–294
McNamara PJ, Levy G (1981) Combined effect of concentration dependent protein binding and Michaelis-Menten kinetics on time course of drug concentrations in plasma. Acta Pharm Fenn 90: 99–106
Melethil S, Conway WD (1976) Urinary excretion of probenecid and its metabolites in humans as a function of dose. J Pharm Sci 65: 861–865
Metzler CM, Elfring GL, McEwen AJ (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 30: 562
Neff NH, Tozer TN, Brodi BB (1967) Application of steady-state kinetics to studies of the transfer of 5-hydroxyindoleacetic acid from brain to plasma. J Pharmacol Exp Ther 158: 214–218
Perel JM, Dayton PG, Yü TF, Gutman AB (1971) Studies of the renal excretion of probenecid acyl glucuronide in man. Eur J Clin Pharmacol 3: 106–112
Rubin GM, Tozer TN (1984) Theoretical considerations in the calculation of bioavailability of drugs exhibiting Michaelis-Menten elimination kinetics. J Pharmacokinet Biopharm 12: 437–450
Sedman AJ, Wagner JG (1974) Quantitative pooling of Michaelis-Menten equations in models with parallel metabolite formation paths. J Pharmacokinet Biopharm 2: 149–160
Selen A, Amidon GL, Welling PG (1982) Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci 71: 1238–1242
Tozer TN (1984) Implications of altered plasma protein binding in disease states. In: Benet LZ, Massoud N, Gambertoglio JG (eds) Pharmacokinetic basis for drug treatment. Raven Press, New York, pp 173–193
van Praag HM, Korf J (1974) Serotonin metabolism in depression: Clinical application of the probenecid test. Int J Pharmacopsychiatr 9: 35–51
Wagner JG (1975) Nonlinear pharmacokinetics. In: Wagner JG (ed) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Hamilton, Illinois, pp 247–284
Wagner JG (1985) Theophylline, pooled Michaelis-Menten parameters (Vmax and Km) and implications. Clin Pharmacokinet 10: 432–442
Øie S, Tozer TN (1979) Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 68: 1203–1205
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Emanuelsson, B.M., Beermann, B. & Paalzow, L.K. Non-linear elimination and protein binding of probenecid. Eur J Clin Pharmacol 32, 395–401 (1987). https://doi.org/10.1007/BF00543976
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00543976